{
    "root": "65ee7bca-fa06-45b3-ac02-2119b92ba347",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Pioglitazone",
    "value": "20250318",
    "ingredients": [
        {
            "name": "PIOGLITAZONE HYDROCHLORIDE",
            "code": "JQT35NPK6C",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_8229"
        },
        {
            "name": "CARBOXYMETHYLCELLULOSE CALCIUM",
            "code": "UTY7PDF93L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_85146"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00840"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        }
    ],
    "indications": {
        "text": "monotherapy combination therapy pioglitazone tablets indicated adjunct diet exercise improve glycemic control adults type 2 diabetes mellitus multiple settings [ ( 14 ) ] . important limitations pioglitazone tablets exert antihyperglycemic effect presence endogenous insulin . pioglitazone tablets used treat type 1 diabetes diabetic ketoacidosis , would effective settings . caution patients liver disease [ ( 5.3 ) ] .",
        "doid_entities": [
            {
                "text": "type 2 diabetes mellitus (DOID:9352)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9352"
            },
            {
                "text": "diabetes (DOID:9351)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9351"
            },
            {
                "text": "diabetic ketoacidosis (DOID:1837)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1837"
            },
            {
                "text": "liver disease (DOID:409)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_409"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 initiate pioglitazone tablets 15 mg 30 mg daily . limit initial dose 15 mg daily patients nyha class ii heart failure . ( 2.1 ) \u2022 inadequate glycemic control , dose increased 15 mg increments maximum 45 mg daily . ( 2.1 ) \u2022 obtain liver tests starting pioglitazone tablets . abnormal , caution treating pioglitazone tablets , investigate probable cause , treat ( possible ) follow appropriately . monitoring liver tests pioglitazone tablets recommended patients without liver disease . ( 5.3 )",
        "doid_entities": [
            {
                "text": "liver disease (DOID:409)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_409"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "pioglitazone available 15 mg , 30 mg , 45 mg tablets follows : pioglitazone tablets usp , 15 mg white off-white , round , biconvex , uncoated tablets , debossed \u201c 31 \u201d one side \u201c h \u201d side . carton 100 ( 10 tablets per blister pack x 10 ) , ndc 0904-7090-61 pioglitazone tablets usp , 30 mg white off-white , round , flat faced , beveled edge uncoated tablets , debossed \u201c 32 \u201d one side \u201c h \u201d side . carton 100 ( 10 tablets per blister pack x 10 ) , ndc 0904-7096-61 storage store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] . keep container tightly closed , protect light , moisture humidity .",
    "adverseReactions": "\u2022initiation patients established nyha class iii iv heart failure [ boxed warning ] . \u2022 patients known hypersensitivity pioglitazone component pioglitazone tablets .",
    "indications_original": "Monotherapy and Combination Therapy\n                     \n                     Pioglitazone tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings [see Clinical Studies (14)].\n                     \n                     Important Limitations of Use\n                     \n                      Pioglitazone tablets exert its antihyperglycemic effect only in the presence of endogenous insulin. Pioglitazone tablets should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings.\n                      Use caution in patients with liver disease [see Warnings and Precautions (5.3)].",
    "contraindications_original": "\u2022 Initiate pioglitazone tablets at 15 mg or 30 mg once daily. Limit initial dose to 15 mg once daily in patients with NYHA Class I or II heart failure. (2.1) \u2022 If there is inadequate glycemic control, the dose can be increased in 15 mg increments up to a maximum of 45 mg once daily. (2.1) \u2022 Obtain liver tests before starting pioglitazone tablets. If abnormal, use caution when treating with pioglitazone tablets, investigate the probable cause, treat (if possible) and follow appropriately. Monitoring liver tests while on pioglitazone tablets are not recommended in patients without liver disease. (5.3)",
    "warningsAndPrecautions_original": "Pioglitazone\u00a0is available in 15 mg, 30\u00a0mg, and 45\u00a0mg tablets as follows:\n                     \n                     Pioglitazone Tablets USP, 15 mg are white to off-white, round, biconvex, uncoated tablets, debossed with \u201c31\u201d on one side and \u201cH\u201d on other side.\n                  Carton of 100 (10 tablets per blister pack x 10), NDC 0904-7090-61\n                  \n                     \n                     Pioglitazone Tablets USP, 30 mg are white to off-white, round, flat faced, beveled edge uncoated tablets, debossed with \u201c32\u201d on one side and \u201cH\u201d on other side.\n                  Carton of 100 (10 tablets per blister pack x 10), NDC 0904-7096-61\n                  \n                     \n                     Storage\n                     \n                     \n                      Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [see USP Controlled Room Temperature]. Keep container tightly closed, and protect from light, moisture and humidity.",
    "adverseReactions_original": "\u2022Initiation in patients with established NYHA Class III or IV heart failure [see Boxed Warning].\n                     \n                     \n                        \u2022\u00a0Use in patients with known hypersensitivity to pioglitazone or any other component of pioglitazone tablets.",
    "drug": [
        {
            "name": "Pioglitazone",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_8228"
        }
    ]
}